Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued

January 9, 2024 8:00 AM

Analysts suggest Nascent Value at $0.60 to $2.84 per shareNORTH PALM BEACH, FL / ACCESSWIRE / January 9, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies focused on treating various cancers, announced today that the Company was featured in an independent research report by Marble Arch ResearchThe report can be viewed on the Company...

Read more

FluoGuide Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001

January 8, 2024 6:00 AM

KØBENHAVN, DENMARK / ACCESSWIRE / January 8, 2024 / FluoGuide A/S (STO:FLUO)Strong phase II data on FG001 in three indications: brain, head & neck, lung cancersAssessing potential of photothermal therapy in aggressive brain cancerClinical trial to be used for registration of FG001 in fluorescent guided surgery of aggressive brain cancer expected to start in 2025Phase II trial in head & neck cancer, which offers a range of opportunities with...

Read more

MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 8, 2024 2:20 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 8, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PST in San Francisco, California. The company's Chief Financial Officer, Lucinda Crabtree, Ph.D., and Chief Research and Development Officer, Tim Demuth, M.D., Ph.D., will also...

Read more

Radiance Therapeutics to Present at the Biotech Showcase 2024 in San Francisco

January 5, 2024 7:50 AM

EMERYVILLE, CA / ACCESSWIRE / January 5, 2024 / Radiance Therapeutics, an innovation leader in ophthalmic devices, is delighted to announce that its CEO, Laurence Marsteller, MSc. MD, will be presenting the company at Biotech Showcase™ 2024 in San Francisco, CA.This year, registered attendees can view Radiance Therapeutics' presentation live and also access a recorded version.Radiance Therapeutics will be presenting on Tuesday, January 9, 2024,...

Read more

Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

January 4, 2024 4:15 PM

TORONTO, ON / ACCESSWIRE / January 4, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that company management plans to participate in the 2024 Dermatology Summit on January 7, 2024 as well as in one-on-one meetings alongside the J.P. Morgan 42nd Annual Healthcare Conference from January 8-11, 2024 in San...

Read more

Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide

January 4, 2024 9:05 AM

Final results from a human pilot study show DehydraTECHTM-powered semaglutide outperforms Rybelsus®:Sustained higher levels of semaglutide in blood;Better blood glucose control;Faster achievement of peak drug delivery; andReduced side effects.KELONA, BC / ACCESSWIRE / January 4, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces positive final results from...

Read more

Seraxis' Manufacturing Suite Completes GMP Quality System Audit Ahead of SR-02 IND Filing and Transplantation of Pancreatic Clusters to Patients With Type 1 Diabetes

January 4, 2024 9:00 AM

GMP-compliant manufacturing puts SR-02 on track to be industry's second clinical-stage stem cell derived pancreatic islet transplant program. The third-party auditor's FDA six-system approach yielded no critical nor major observations of Seraxis' quality system for the production of GMP-grade organs from pancreas-derived stem cells. Dr. William Rust, CEO, will present further data on the development of SR-02 and follow-on immune-cloaked SR-03 on...

Read more

BioInvent Announces 2024 Strategic Priorities and Anticipated Milestones

January 4, 2024 8:45 AM

Data from seven different clinical studies expected throughout the year, including combination data for the two lead programs BI-1808 and BI-1206 in H1/mid-2024Well-financed with 1358 SEK million (~USD 132M), as of September 30, 2023LUND, SE / ACCESSWIRE / January 4, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...

Read more

MRES: M2MMA Gears Up for a Landmark Year in 2024

January 2, 2024 9:35 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / January 2, 2024 / Institute of Biomedical Research Corp. (OTC PINK: MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to announce the following updates with its M2MMA division: As M2MMA embarks on 2024, the...

Read more

NovAccess Global Announces $10.7 Million Financing

January 2, 2024 8:00 AM

Establishes Strong Financial Base To Advance Development of Novel Cancer ImmunotherapiesCLEVELAND, OH / ACCESSWIRE / January 2, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced it entered into a securities purchase agreement with an affiliate of Sumner Global LLC ("Sumner") for a total financing of $10.7 million. Pursuant to the agreement, Sumner agreed to...

Read more

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

December 20, 2023 4:05 PM

- About 550 patients will be treated once weekly for 12 weeks -- STAR-1 topline results expected in first quarter of 2025 -- Acne affects about 50 million patients in the U.S. -SAN DIEGO, CA / ACCESSWIRE / December 20, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that it successfully...

Read more

Canyon Labs Announces Senior Leadership Changes

December 20, 2023 9:00 AM

Medical Device and Pharmaceutical Veterans Join Leadership of Canyon Labs to Bring Best-in-Class Customer Experience.SALT LAKE CITY, UT / ACCESSWIRE / December 20, 2023 / Canyon Labs announces the appointment of Sarah Ptach as President and Wendy Mach as Senior Director of Technical Services to further enhance leadership expertise in the pharmaceutical and medical device service industries.These new leadership roles represent a commitment to...

Read more

Cenna Announces Appointment of David H. Crean to Board of Directors

December 19, 2023 9:00 PM

Cardiff Advisory Managing Partner Has Decades of Experience Guiding Life Sciences and Healthcare Companies Through Pivotal Growth, Won the Alzheimer's Association of San Diego 2023 Hope Award and Has Been Recognized as One of San Diego's 500 Most Influential People for the Last Four YearsLA JOLLA, CA / ACCESSWIRE / December 19, 2023 / Cenna Biosciences today announced the appointment of David H. Crean to the Cenna Board of Directors effective...

Read more

Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023

December 19, 2023 4:15 PM

SAN DIEGO, CA / ACCESSWIRE / December 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), today announced that the Company's Special Meeting of Stockholders (the "Special Meeting") to be held on December 20, 2023 at 9:00 a.m. Pacific Time has been postponed due to lack of the required quorum.A quorum consists of one third of the outstanding shares of our common stock (present in person (including virtually) or...

Read more

Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk

December 19, 2023 8:00 AM

NORTH PALM BEACH, FL / ACCESSWIRE / December 19, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers, is pleased to announce that the Company has completed payment of all outstanding variable convertible debt obligations.On August 30, 2023, the Company and the Noteholder YA II...

Read more

Canopus BioPharma Inc., dba Blue Heaven Coffee Inc., Announces Amendment to PepsiCo (Nasdaq: PEP) Distributor Partnership Beverage Agreement

December 19, 2023 7:00 AM

LAS VEGAS, NV / ACCESSWIRE / December 19, 2023 / Operating as Blue Heaven Coffee Inc. (BHC), Canopus Biopharma Inc. (OTC PINK:CBIA) is thrilled to announce a fully executed amendment to its original distributor partnership beverage agreement with the world-renowned beverage company, PepsiCo, Inc. (Nasdaq: PEP). The original agreement (announced to markets on September 7, 2023) established PepsiCo as the exclusive cold-beverage provider for BHC's...

Read more

BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research

December 19, 2023 4:00 AM

German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.HEIDELBERG, GERMANY / ACCESSWIRE / December 19, 2023 / BioMed X announced today a new joint research project with Ono Pharmaceutical Co., Ltd, marking the start of the collaboration between the German biomedical research institute and one of the largest pharmaceutical companies in Japan. The...

Read more

Shaperon Completes Investigator Meeting in the U.S. for Atopic Dermatitis Treatment 'HY209gel'

December 18, 2023 9:30 AM

SEOUL, SOUTH KOREA / ACCESSWIRE / December 18, 2023 / Shaperon Inc. (378800.KQ), a KOSDAQ-listed, Korean biotech company developing innovative immune drugs, has announced the successful completion of an investigator meeting for the Phase 2 clinical trial for the atopic dermatitis treatment ‘HY209gel' in Dallas, Texas, USA on December 9, 2023. The investigator meeting was organized to introduce and discuss the operational progress and future...

Read more

CDBT Registers Magistrates Court of Queensland Judgments against Kenneth Maciora / Empire Relations Group

December 16, 2023 6:30 PM

ARUNDEL, AUSTRALIA / ACCESSWIRE / December 16, 2023 / China Dasheng Biotechnology Co. (OTC Pink: CDBT) advises that it has been issued 2 Judgements, $17,129.13 and $17,066.59 in its favor against Kenneth Maciora and Empire Relations Group, Inc., and those Judgements have been registered with the Magistrates Court of Queensland on November 29, 2023.Background:As disclosed on October 9, 2023, CDBT formally terminated the China Dasheng...

Read more

Edesa Biotech Reports Fiscal Year 2023 Results

December 15, 2023 4:10 PM

TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2023 and provided an update on its business.During the year, Edesa reported favorable results from two clinical studies and achieved multiple regulatory and operational...

Read more